Drugs / GSK461364
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00536835 | Aug 2007 → Sep 2009 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK461364 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00536835 ↗ |
| Known as | GSK-461364A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908394 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase PLK1 inhibitor” CHEMBL1908394 ↗ |
| Modality | Small molecule | — CHEMBL1908394 ↗ |
| Target | PLK1 | “Serine/threonine-protein kinase PLK1 inhibitor” CHEMBL1908394 ↗ |